Explore how retatrutide, amylin therapies, and oral agents could expand obesity treatment beyond semaglutide and tirzepatide.
Daniel Drucker, MD
Advertisement
Daniel Drucker, MD, is a professor in the Departments of Medicine and Laboratory Medicine and Pathobiology at the University of Toronto.
Articles by Daniel Drucker, MD
Daniel Drucker, MD, discusses gastrointestinal effects, hydration, pregnancy planning, and unanswered long-term safety questions.
An endocrinologist discusses the importance of history, comorbidities, lifestyle care, and outcomes beyond weight loss when choosing obesity treatment.
Daniel Drucker, MD, who coauthored the recent Endocrine Society scientific statement on obesity medicines, discusses key takeaways for primary care physicians.
Advertisement
Latest Updated Articles
Endocrine Society Obesity Statement Calls for Goals Beyond Weight LossSeptember 18th 2026
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Once-Monthly Olanzapine Injection for Adults With Schizophrenia
2
9 Drugs Approved for Primary Care: Q3 2026
3
Multicomponent Strategies to Ease Vaccination Pain and Fear Across Ages
4
Abbott Gains FDA Approval for CardioMEMS Update Letting Heart Failure Patients View Pressure Readings on Their Phones
5